These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34547175)

  • 1. Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study.
    Wijkman MO; Malachias MVB; Claggett BL; Cheng S; Matsushita K; Shah AM; Jhund PS; Coresh J; Solomon SD; Vardeny O
    J Clin Hypertens (Greenwich); 2021 Oct; 23(10):1887-1896. PubMed ID: 34547175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparent resistant hypertension and the risk of vascular events and mortality in patients with manifest vascular disease.
    van der Sande NGC; de Beus E; Bots ML; Voskuil M; Blankestijn PJ; Visseren F; Spiering W;
    J Hypertens; 2018 Jan; 36(1):143-150. PubMed ID: 28763342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency & factors associated with apparent resistant hypertension among Ghanaians in a multicenter study.
    Ayisi-Boateng NK; Mohammed A; Opoku DA; Sarfo FS
    J Clin Hypertens (Greenwich); 2020 Sep; 22(9):1594-1602. PubMed ID: 32815641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent treatment-resistant hypertension associated lifetime cardiovascular risk in a longitudinal national registry.
    Ebinger JE; Kauko A; ; Bello NA; Cheng S; Niiranen T
    Eur J Prev Cardiol; 2023 Aug; 30(10):960-968. PubMed ID: 36866422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease.
    Smith SM; Huo T; Gong Y; Handberg E; Gulati M; Merz CN; Pepine CJ; Cooper-DeHoff RM
    J Womens Health (Larchmt); 2016 Oct; 25(10):996-1003. PubMed ID: 27224417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
    Smith SM; Huo T; Delia Johnson B; Bittner V; Kelsey SF; Vido Thompson D; Noel Bairey Merz C; Pepine CJ; Cooper-Dehoff RM
    J Am Heart Assoc; 2014 Feb; 3(1):e000660. PubMed ID: 24584740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of Individuals With Apparent Resistant Hypertension Using Contemporary Guidelines: Insights From CV-QUIC.
    Ebinger JE; Gluckman TJ; Magraner J; Chiu ST; Rider D; Thomas C; Das SR; Ho PM; Shreenivas S; Bradley S
    Hypertension; 2023 Sep; 80(9):1845-1855. PubMed ID: 37357771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Muntner P; Davis BR; Cushman WC; Bangalore S; Calhoun DA; Pressel SL; Black HR; Kostis JB; Probstfield JL; Whelton PK; Rahman M;
    Hypertension; 2014 Nov; 64(5):1012-21. PubMed ID: 25259745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study.
    Rodriguez CJ; Swett K; Agarwal SK; Folsom AR; Fox ER; Loehr LR; Ni H; Rosamond WD; Chang PP
    JAMA Intern Med; 2014 Aug; 174(8):1252-61. PubMed ID: 24935209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Hypertension: Which Goal for Which Patient?
    Jarraya F
    Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of heart failure in ambulatory resistant hypertension: a meta-analysis of observational studies.
    Coccina F; Salles GF; Banegas JR; Hermida RC; Bastos JM; Cardoso CRL; Salles GC; Sánchez-Martínez M; Mojón A; Fernández JR; Costa C; Carvalho S; Faia J; Pierdomenico SD
    Hypertens Res; 2024 May; 47(5):1235-1245. PubMed ID: 38485774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: an open-label, prospective, observational study.
    Ionescu DD;
    Clin Drug Investig; 2009; 29(12):767-76. PubMed ID: 19888783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
    Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
    PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study.
    Tanner RM; Calhoun DA; Bell EK; Bowling CB; Gutiérrez OM; Irvin MR; Lackland DT; Oparil S; McClellan W; Warnock DG; Muntner P
    Am J Kidney Dis; 2014 May; 63(5):781-8. PubMed ID: 24388119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
    Kjeldsen SE; Berge E; Bangalore S; Messerli FH; Mancia G; Holzhauer B; Hua TA; Zappe D; Zanchetti A; Weber MA; Julius S
    Blood Press; 2016; 25(2):83-92. PubMed ID: 26511535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Health and Transition From Controlled Blood Pressure to Apparent Treatment Resistant Hypertension: The Jackson Heart Study and the REGARDS Study.
    Akinyelure OP; Sakhuja S; Colvin CL; Clark D; Jaeger BC; Hardy ST; Howard G; Cohen LP; Irvin MR; Tanner R; Carey RM; Muntner P
    Hypertension; 2020 Dec; 76(6):1953-1961. PubMed ID: 33131312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study.
    Douros A; Tölle M; Ebert N; Gaedeke J; Huscher D; Kreutz R; Kuhlmann MK; Martus P; Mielke N; Schneider A; Schuchardt M; van der Giet M; Schaeffner E
    Eur Heart J; 2019 Jul; 40(25):2021-2028. PubMed ID: 30805599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Apparent Therapy-Resistant Hypertension and Its Effect on Outcome in Patients With Chronic Kidney Disease.
    de Beus E; Bots ML; van Zuilen AD; Wetzels JF; Blankestijn PJ;
    Hypertension; 2015 Nov; 66(5):998-1005. PubMed ID: 26351024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance.
    Fleg JL; Evans GW; Margolis KL; Barzilay J; Basile JN; Bigger JT; Cutler JA; Grimm R; Pedley C; Peterson K; Pop-Busui R; Sperl-Hillen J; Cushman WC
    Hypertension; 2016 Oct; 68(4):888-95. PubMed ID: 27504006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.